Despite the fact that stroke reduction has not been directly demonstrated with the use of SGLT-2 inhibitors, diabetic patients with atherosclerotic disease receive enormous benefit in the global reduction of cardiovascular events, notably reduction of morbidity from heart failure. Here, SLC5A2 is linked to stroke disorder.